AZTA earnings analysis
What we found in AZTA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Azenta reported a Q2 FY2026 revenue of $145 million, slightly missing estimates of $148 million. The company's diluted EPS was -$3.49, significantly lower than the expected $0.13, largely impacted by a goodwill impairment charge of $149 million. Despite some recent revenue growth in segments, management revised down its full-year revenue guidance to a range of $603 to $621 million.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Slightly Misses Estimates
- Reported revenue was $145 million, compared to estimates of $148 million.
- Significant EPS Miss
- Diluted EPS was -$3.49, missing analyst expectations of $0.13.
- Goodwill Impairment Charge
- A non-cash goodwill impairment charge of $149 million significantly affected earnings.
- Segment Revenue Growth
- SMS segment revenue grew 1.6% YoY to $81.1 million, while Multiomics grew 0.3% to $63.7 million.
- Cash Position Remains Strong
- Cash and cash equivalents totaled $234 million as of March 31, 2026.
- Improved Operating Cash Flow
- Operating cash inflow was $34.4 million for the six months ended March 31, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Failure to Complete B Medical Sale
- Thelema has not secured financing for the B Medical Systems acquisition, creating uncertainty.
- Goodwill and Intangible Assets Impairment
- Goodwill impairments of $149.1 million may indicate further financial instability.
- Increased Operating Expenses
- Total operating expenses surged to $227.8 million due to the goodwill impairment.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-3.49
- Gross margin
- 43%
- Operating margin
- -114.5%
- Segment
- Sample Management Solutions: $81.1 million
- Segment
- Multiomics: $63.7 million
What they said about what is next.
Outlook revised down from previous expectations following impairment charges and declining revenue growth.
The filing reads worse than the one before it.
What came before.
- 10-Q · February 5, 2026
- Azenta reported quarterly revenue of $148,642,000 (reported as 148,642 in the filing) — up modestly from $147,436,000 a year earlier — but reported a GAAP net loss of $15,432,000 (diluted loss per share $0.34). Gross…
- 10-Q · May 9, 2025
- Azenta reported quarterly revenue of $143,418,000 (up $7,063,000 or ~5.2% vs. $136,355,000 a year ago) with gross profit of $65,886,000 and a gross margin of ~45.9%. The company remains loss‑making: diluted net loss per…
- 10-Q · February 10, 2025
- Azenta reported quarterly revenue of $147.51 million (three months ended December 31, 2024) versus $141.73 million a year ago, with gross profit rising to $68.671 million. Operating loss narrowed to $(11.353) million…
- 10-Q · August 6, 2024
- Azenta reported Q3 revenue of $172.809M, up $6.861M (4.1%) versus $165.948M a year ago, with gross profit of $69.056M (up $1.051M). Operating loss improved to $(14.754)M from $(15.836)M a year ago, but the company…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AZTA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever